Open AccessSHV-14, a Novel β-Lactamase Variant in Klebsiella pneumoniae Isolates from Nijmegen, The Netherlands
Author(s) -
Meifang Yuan,
Lucinda M. C. Hall,
J.A.A. Hoogkamp-Korstanje,
David M. Livermore
Publication year - 2001
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.45.1.309-311.2001
Subject(s) - klebsiella pneumoniae , cephalosporin , microbiology and biotechnology , ceftazidime , biology , enterobacteriaceae , klebsiella , virology , genotype , mutation , gene , genetics , antibiotics , escherichia coli , pseudomonas aeruginosa , bacteria
Four ceftazidime-resistant isolates of a Klebsiella pneumoniae strain were collected from intensive care unit patients in Nijmegen, The Netherlands. These isolates had TEM-29 and SHV-14 beta-lactamases. SHV-14 is a novel variant, with two substitutions compared with the sequence of SHV-1: Ile8Phe and Arg43Ser. Its gene also had a silent C-->T mutation at nucleotide 481. The SHV-14 enzyme had slightly higher V(max) rates than SHV-1 for oxyimino-aminothiazolyl cephalosporins, but this activity was insufficient for the enzyme to count as an extended-spectrum beta-lactamase.